Please assess the completion status of the following clinical trial:

Trial Title: Treatment Options for Protease Inhibitor-exposed Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected child 3 to 5 years of age at time of screening for this trial if enrolled from outside or any age if enrolled from control arm of Neverest II.~* Reliable history or documented exposure to NVP used as part of PMTCT~* Initiated antiretroviral therapy with LPV/r at age less than 36 months~* Receiving LPV/r-based ART for at least 12 months~* At least one viral load measurement less than 50 copies/ml conducted as part of screening for the study~* ALT measurement grade I or less (DAIDS Toxicity Tables 2004) (Appendix A). These may be repeated until ALTs normalize if necessary.~Exclusion criteria:~* Prior treatment with any NNRTI drug as part of a therapeutic regimen~* Substitution of other NRTI drugs (instead of 3TC and D4T which are the standard first line regimen) will be allowed.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Lopinavir/ritonavir (LPV/r) (Type: ACTIVE_COMPARATOR): Participants are assigned to remain on their current LPV/r-based antiretroviral regimen. Ritonavir-boosted lopinavir syrup was given twice per day at 230 mg/m\^2 per dose. Children able to swallow tablets were given 1 tablet twice per day (200 mg lopinavir/50 mg ritonavir) if body surface area was less than 0.9m\^2 or 2 tablets twice per day if body surface area was 0.9m\^2 or higher.
- Group 2: Efavirenz (EFV) (Type: EXPERIMENTAL): Participants are assigned to switch to an EFV-based antiretroviral regimen. Efavirenz was prescribed once daily in the evening at 200 mg for weights of 10 kg to 13.9 kg (22-30 lb) and 300mg for weights of 14 kg to 24.9 kg (31-55 lb). Efavirenz was available in 50-mg and 200-mg capsules. If children were unable to swallow capsules, caregivers were shown how to open the capsules and dissolve the contents in water.
- Group D: Stavudine (D4T) (Type: ACTIVE_COMPARATOR): Children are assigned to remain on their current antiretroviral regimen, which includes D4T. D4T was given at 1 mg/kg twice daily
- Group A: Abacavir (ABC) (Type: EXPERIMENTAL): Children stop taking D4T and switch to ABC. ABC was given at 8 mg/kg twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).